Limited cross-variant immune response from SARS-CoV-2 Omicron BA.2 in naive but not previously infected outpatients.

ABSTRACT: Omicron is currently the dominant SARS-CoV-2 variant and several sublineages have emerged. Questions remain about the impact of previous SARS-CoV-2 exposure on cross-variant immune responses elicited by BA.2 infection compared to BA.1. Here we show that without previous history of COVID-19, BA.2 infection induces a reduced immune response against all variants of concern (VOC) compared to BA.1 infection. The absence of ACE2 binding in sera of previously naïve BA.1 and BA.2 patients indicates a lack of meaningful neutralization. In contrast, anti-spike antibody levels and neutralizing activity greatly increased in the BA.1 and BA.2 patients with a previous history of COVID-19. Transcriptome analyses of peripheral immune cells showed significant differences in immune response and specific ant

SUBMITTER: Lee HK 

PROVIDER: S-EPMC9016656 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature